Device Trial Radar · NCT05224245
ACURATE Prime XL Human Feasibility Study
Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 3, 2022
Primary completion
Jun 16, 2022
Study completion May 24, 2023
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Feb 4, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate feasibility and safety of the ACURATE Prime™ XL Transfemoral Aortic Valve System for transcatheter aortic valve implantation (TAVI) in subjects with severe native aortic stenosis who are indicated for TAVI.
Conditions
- Aortic Stenosis
Interventions
ACURATE Prime XL Transfemoral Aortic Valve SystemDevice
ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Device SuccessTime frame: Through discharge or 7 days post procedure
- Number of participants who died or experienced a strokeTime frame: Through 30 Days post procedure
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
The Prince Charles Hospital
Brisbane, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.